Edition:
United States

Bellerophon Therapeutics Inc (BLPH.OQ)

BLPH.OQ on NASDAQ Stock Exchange Global Market

2.32USD
20 Apr 2018
Change (% chg)

$0.14 (+6.42%)
Prev Close
$2.18
Open
$2.20
Day's High
$2.36
Day's Low
$2.19
Volume
121,035
Avg. Vol
42,655
52-wk High
$2.71
52-wk Low
$1.00

Latest Key Developments (Source: Significant Developments)

Bellerophon Therapeutics reports Q3 loss per share $0.22
Tuesday, 7 Nov 2017 08:30am EST 

Nov 7 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon provides business update and reports third quarter 2017 financial results.Q3 loss per share $0.22.Says ‍ phase 2a study for inopulse met its primary endpoint​.  Full Article

Bellerophon Therapeutics says selling stockholders may offer, resell up to 38.9 mln shares - SEC filing
Tuesday, 24 Oct 2017 05:26pm EDT 

Oct 24 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon Therapeutics Inc files to say selling stockholders may offer and resell up to 38.9 million shares of co's common stock - SEC filing.Bellerophon Therapeutics Inc - the selling stockholders will receive all of the proceeds from any sales of the shares offered.  Full Article

Bellerophon announces $23 million private placement
Wednesday, 27 Sep 2017 08:30am EDT 

Sept 27 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon announces $23 million private placement.Bellerophon Therapeutics Inc - ‍financing was led by Puissance Capital Management and Venrock Healthcare Capital Partners​.Bellerophon Therapeutics Inc - will sell about 19.4 million shares of stock, warrants to purchase about 19.4 million shares of stock for about $23.4 million.  Full Article

Bellerophon announces positive top line Phase 2 data of INOpulse
Tuesday, 5 Sep 2017 08:30am EDT 

Sept 5 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon announces positive top line Phase 2 data of INOpulse for treatment of Pulmonary Hypertension associated with Chronic Obstructive Pulmonary Disease.Bellerophon Therapeutics Inc - ‍acute results showed a statistically significant increase in blood vessel volume on INO compared to baseline​.Bellerophon Therapeutics Inc - ‍study therapy was well tolerated with no related safety concerns​.Bellerophon Therapeutics Inc - ‍is currently conducting a Phase 3 trial for INOpulse for treatment of Pulmonary Arterial Hypertension​.Bellerophon Therapeutics Inc - ‍top-line data for Phase 3 trial of INOpulse expected in 2018​.  Full Article

Bellerophon reports Q2 loss per share $0.12
Monday, 7 Aug 2017 08:00am EDT 

Aug 7 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon reports second quarter 2017 financial results and provides business update.Q2 loss per share $0.12.Bellerophon Therapeutics - Anticipate reporting top line results for inovation-1 phase 3 trial in PAH in 2018.  Full Article

Bellerophon announces FDA agreement on phase 2B study design for Inopulse
Thursday, 3 Aug 2017 08:30am EDT 

Aug 3 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon announces FDA agreement on phase 2B study design for Inopulse in pulmonary hypertension associated with interstitial lung disease (PH-ILD).Bellerophon Therapeutics -‍met with FDA in June to present positive results from its recently completed phase 2A study in idiopathic pulmonary fibrosis​.Bellerophon Therapeutics Inc - ‍agency accepted co's proposed phase 2B study design as well as an ind application to assess effect of inopulse​.  Full Article

CVI Investments reports 5.7 percent passive stake in Bellerophon Therapeutics as of May 10
Thursday, 18 May 2017 11:49am EDT 

May 18 (Reuters) - CVI Investments Inc :CVI Investments Inc reports 5.7 percent passive stake in Bellerophon Therapeutics Inc as of May 10, 2017 - SEC filing.  Full Article

Bellerophon Q1 loss per share $0.60
Monday, 15 May 2017 08:00am EDT 

May 15 (Reuters) - Bellerophon Therapeutics Inc ::Bellerophon reports first quarter 2017 financial results and provides business update.Q1 loss per share $0.60.Bellerophon Therapeutics - believes that as of march 31, 2017, it has sufficient funds to satisfy its operating cash needs for at least next 12 months.Bellerophon Therapeutics - at March 31, 2017, co had cash and cash equivalents, restricted cash and marketable securities of $17.1 million compared to $20.5 million at December 31, 2016.  Full Article

Bellerophon Therapeutics says co terminated sales agreement - sec filing
Tuesday, 2 May 2017 06:18pm EDT 

May 2 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon Therapeutics says effective April 26 , co terminated at market issuance sales agreement entered into on May 27, 2016 - SEC Filing.Bellerophon Therapeutics Inc - Decided to terminate sales agreement because it does not intend to utilize sales agreement to raise additional capital.  Full Article

Bellerophon Therapeutics reports Q4 loss per share of $0.37
Monday, 13 Mar 2017 07:30am EDT 

Bellerophon Therapeutics Inc : Bellerophon reports fourth quarter 2016 financial results and provides business update . Q4 loss per share $0.37 .Enrollment continues in Inovation-1, with topline results targeted in mid-2018 and interim read expected around end of 2017.  Full Article

BRIEF-Bellerophon Q4 Loss Per Share $0.44

* BELLEROPHON PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS